Latest News

Image credit: peterschreiber.media | stock.adobe.com
Data From Phase III Extension Trial Show Long-Term Safety, Efficacy of Qulipta in Migraine Prevention

April 12th 2024

Multicenter, open-label, 156-week extension trial finds that Qulipta (atogepant) reduced migraine days and acute medication use in patients with chronic or episodic migraine.

© photon_photo - © photon_photo - stock.adobe.com
Taking eCOA Delivery Off the Critical Path to First Patient In

April 12th 2024

The Role of Human Oversight With Artificial Intelligence in Clinical Research
The Role of Human Oversight With Artificial Intelligence in Clinical Research

April 12th 2024

Image credit: Kaikoro | stock.adobe.com
Generative AI-Enabled/Augmented Clinical Trials: The Road Ahead

April 11th 2024

Image credit: cendeced | stock.adobe.com
Meta-Analysis of Randomized Clinical Trials Show Psilocybin for Depression, Anxiety Has Tolerable Adverse Effects

April 11th 2024

Conference Coverage

View All
SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials
SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials

February 19th 2024

SCOPE 2024: Alex Deyle of Flatiron Health Discusses RWD in Clinical Trials
SCOPE 2024: Alex Deyle of Flatiron Health Discusses RWD in Clinical Trials

February 14th 2024

SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators
SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators

February 13th 2024

SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden
SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden

February 13th 2024

Latest Videos
Podcasts
© Alex from the Rock - © Alex from the Rock - stock.adobe.com
Rinol Alaj, Jaclyn Patterson, Applied Clincial Trials Podcast

All News

© 2024 MJH Life Sciences

All rights reserved.